<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="id">4196</item><item key="factors"><item><item key="GSM77485"><item key="TREATMENT">control</item><item key="TIME">not specified</item></item></item><item><item key="GSM774852"><item key="TREATMENT">IFNalpha</item><item key="TIME">6 h</item></item></item><item><item key="GSM774853"><item key="TREATMENT">IFNalpha</item><item key="TIME">24 h</item></item></item><item><item key="GSM774854"><item key="TREATMENT">IL28B</item><item key="TIME">6 h</item></item></item><item><item key="GSM774855"><item key="TREATMENT">IL28B</item><item key="TIME">24 h</item></item></item><item><item key="GSM774856"><item key="TREATMENT">T Poly IC</item><item key="TIME">not specified</item></item></item></item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">Recent identification of IL28B gene polymorphisms associated with hepatitis C virus (HCV) clearance suggests a role for type III...</item><item key="pubmed_id">22248663</item><item key="geo_gse_id">E-GEOD-31264</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">2</item><item key="sample_count">6</item><item key="tags"><item>hepatitis</item><item>hepatitis c</item><item>liver</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">primary-human-hepatocytes-treated-with-ifnalpha-an</item><item key="geo_id_plat">E-GEOD-31264_A-AFFY-44</item><item key="name">Primary human hepatocytes treated with IFNalpha and IL28B</item><item key="created">Sep.16, 2014</item><item key="summary">Recent identification of IL28B gene polymorphisms associated with hepatitis C virus (HCV) clearance suggests a role for type III interferons (IFNs) in hepatitis C infection. The function of type III IFNs in intrinsic antiviral immunity is poorly understood.  Here we show that HCV infection of primary human hepatocytes results in a robust induction of type III but not type I IFNs, leading to IFN- stimulated gene (ISG) expression.  In addition, HCV infection elicits a much broader range of gene expression alterations in addition to ISG induction. The induction of type III IFNs is mediated by IRF3 and NFkB- dependent pathways.  Type III IFN, aside from upregulating ISGs with a different kinetic profile, induces a distinct set of genes from type I IFN, potentially explaining the functional difference between the two types of IFNs. Chimpanzees undergoing experimental HCV infection demonstrated a prompt hepatic induction of IL28, associating with ISG upregulation, but minimal type I IFN induction. Analysis of liver biopsies from HCV-infected patients supported a close correlation among hepatic expression of IL28 and ISGs, but not with type I IFNs.    Our study demonstrates that HCV infection results predominantly in type III IFN induction in the liver and the level of induction correlates with hepatic ISG levels, thus providing a mechanistic explanation for the association between IL28, ISG levels and recovery from HCV infection as well as a potential therapeutic strategy for the treatment of non-responders. Samples were treated with IFN, IL28b and T-PolyC after 6 or 24 hours respectively</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-31264</item><item key="species">human</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-31264/samples/</item></data></biogps>
